Literature DB >> 11112904

Insect sting-inflicted systemic reactions: attitudes of patients with insect venom allergy regarding after-sting behavior and proper administration of epinephrine.

A Goldberg1, R Confino-Cohen.   

Abstract

BACKGROUND: Patients with insect venom allergy are at higher risk for development of a recurrent systemic reaction after re-sting. This risk significantly decreases with venom immunotherapy. Patients with insect venom allergy should be able to distinguish a life-threatening systemic reaction from all other various reactions after an insect sting. Accidental epinephrine injection by EpiPen has been reported in the past. Therefore patients with venom allergy should also be well trained in self-administration of their epinephrine when needed.
OBJECTIVE: Our objective was to assess patients' attitudes regarding after-sting behavior and their capability to correctly self-administer the epinephrine autoinjector.
METHODS: All patients with venom allergy attending our allergy unit either before commencement of or during venom immunotherapy answered a questionnaire addressing various aspects of their intended after-sting behavior. Using an EpiPen trainer device, patients' performance of EpiPen self-administration was evaluated.
RESULTS: Ninety-six patients participated in the study. Seventy-six of them were equipped with an EpiPen device. Less than 30% of these patients carried it at all times. After re-sting, 50 (54%) patients planned to wait for the development of other symptoms before taking any further action. Twenty-two percent of the patients said that after re-sting they would immediately administer their EpiPen. Proper EpiPen administration technique was demonstrated by 44% of the patients. Having not reached the maintenance dose correlated with a better compliance with carrying of the EpiPen. EpiPen instruction provided by an allergist correlated with a better EpiPen administration technique by the patients.
CONCLUSION: Many patients with venom allergy hold wrong ideas about after-sting behavior. Compliance with carrying EpiPen at all times and the ability to correctly administer it are both poor in most patients. Thorough and probably repeated instruction, both written and oral, provided by knowledgeable physicians is mandatory.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11112904     DOI: 10.1067/mai.2000.110927

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  6 in total

Review 1.  Adrenaline in the treatment of anaphylaxis: what is the evidence?

Authors:  Andrew P C McLean-Tooke; Claire A Bethune; Ann C Fay; Gavin P Spickett
Journal:  BMJ       Date:  2003-12-06

2.  Insect sting allergy. A study from 1980 to 2003 of patients who started treatment with venom immunotherapy between 1980 and 1998.

Authors:  Rolf Haye; Liv Kari Døsen
Journal:  Clin Mol Allergy       Date:  2005-08-19

3.  Improving adrenaline autoinjector adherence: A psychologically informed training for healthcare professionals.

Authors:  Béré Mahoney; Elaine Walklet; Eleanor Bradley; Steve O'Hickey
Journal:  Immun Inflamm Dis       Date:  2019-07-09

4.  Childrens' and Parents' Willingness to Join a Smartphone-Based Emergency Response Community for Anaphylaxis: Survey.

Authors:  Michael Khalemsky; David G Schwartz; Tamar Silberg; Anna Khalemsky; Eli Jaffe; Raphael Herbst
Journal:  JMIR Mhealth Uhealth       Date:  2019-08-27       Impact factor: 4.773

5.  Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy.

Authors:  Tamara Eitel; Kim Nikola Zeiner; Katharina Assmus; Hanns Ackermann; Nadja Zoeller; Markus Meissner; Roland Kaufmann; Stefan Kippenberger; Eva Maria Valesky
Journal:  World Allergy Organ J       Date:  2021-04-21       Impact factor: 4.084

6.  Epinephrine: the drug of choice for anaphylaxis-a statement of the world allergy organization.

Authors:  Stephen F Kemp; Richard F Lockey; F Estelle R Simons
Journal:  World Allergy Organ J       Date:  2008-07       Impact factor: 4.084

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.